Amgen Inc. (AMGN-Q)

They bought a pharma company, luckily wasn't blocked by the FTC. Shares jumped 21% in Q3.

His choice in the biotech space.

He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.

A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech

He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.

Facing a patent crisis as proprietary tech is challenged.
Shares have recently sold off.
Will take time to see how prospects play out.
Good hold, but other places to invest for new investors.